Clinical Trial Update: A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of AR-15512 in dry eye disease has completed and results on safety and systemic exposure have been posted. The trial was sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• AR-15512

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Dry Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-08-13